top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Frame 1410148109.png
Frame 100000825.png
Frame i1000008267.png
Frame 1410148108.png
Frame 10000082699.png
Fra 1000008266.png
Frame 1000i008268.png
Frame 1410148110.png
Frame 100070.png
Frame 1410148111.png
valve.png

Mount Sinai Radiologist Presents New AutoBMD AI Data at I-ELCAP Showing High Rates of Previously Undetected Osteoporosis

Oct 9, 2025
2 min read

FOR IMMEDIATE RELEASE

New York, NY — October 9, 2025


New findings from Mount Sinai Hospital demonstrate hat AutoBMD™ AI can identify large numbers of patients with previously undiagnosed osteoporosis and low bone density on routine chest CT scans performed for lung cancer screening. The data were presented today by Mingqian Huang, MD (Icahn School of Medicine at Mount Sinai) at the I-ELCAP 48th International Conference on Screening for Lung Cancer in New York City. Dr. Huang’s profile: https://profiles.mountsinai.org/mingqian-huang Mount Sinai Health System


“Opportunistic screening from existing CT scans can close critical gaps in osteoporosis detection,” said Dr. Morteza Naghavi, President of HeartLung AI, the provider of AutoBMD AI. “By leveraging AutoBMD AI on scans already acquired for heart and lung studies, health systems can surface clinically significant bone loss earlier—without added scan time, cost, or radiation—so patients at risk are not missed.”



About the study

Using AutoBMD AI to analyze standard low-dose chest CTs, investigators observed a substantial prevalence of patients meeting thresholds consistent with osteoporosis or osteopenia who had no prior diagnosis on record. The results underscore the value of integrating bone health assessment into comprehensive CT-based screening programs to enable earlier intervention, fracture prevention, and improved outcomes. (Detailed statistics and methodology available upon request.)


About AutoBMD™ AI

HeartLung's AutoBMD™ is an AI-powered, cloud-based solution for opportunistic bone mineral density measurement using existing CT scans. It is the only DEXA-equivalent, CT-based osteoporosis screening approved by the FDA, applicable to over 25 million CT scans annually and reimbursed by Medicare.


Conference

I-ELCAP 48th International Conference on Screening for Lung Cancer (& 16th Conference on Research for Early Lung Cancer Treatment)October 9–11, 2025 — Goldwurm Auditorium, Icahn School of Medicine at Mount Sinai



Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png
iScreen Shoter - 20261104171348520.jpg

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page